# Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL

> **NCT02656147** · PHASE1 · UNKNOWN · sponsor: **Beijing Doing Biomedical Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **BIOLOGICAL:** Anti-CD19-CAR γδT

## Key facts

- **NCT ID:** NCT02656147
- **Lead sponsor:** Beijing Doing Biomedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10
- **Primary completion:** 2019-04
- **Final completion:** 2020-04
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02656147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02656147, "Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02656147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*